| Abstract |
From 1984 to 2013, we established 29 childhood tumor cell lines, including
13 soft-tissue-sarcoma cell lines. Here, we provide an overview of these
soft-tissue sarcoma cell lines, their origins, characteristics, and
highlight their potential as valuable research tools for fundamental
research and development of new treatments. The cell lines were
established from three patients with rhabdomyosarcoma (RMS), five patients
with Ewing sarcoma family tumors, four patients with rhabdoid tumors, and
one patient with clear cell sarcoma of soft parts. In particular, we
demonstrate the potential of the MRT cell lines in preclinical in vivo and
in vitro studies to evaluate molecular target therapy using gefitinib and
trastuzumab activated antibody-dependent cellular cytotoxicity. Moreover,
the clear cell sarcoma cell line, MP-CCS-SY, was established from a
metastatic tumor in the left Achilles tendon of a 17-year-old girl, which
represents a rare cell line for this cancer, and will help to gain a
better understanding of the molecular biology of this malignancy and serve
as a useful tool for developing boron neutron capture therapy.
|
|---|
